title: Deciphering the therapeutic stem cell strategies of large and midsize pharmaceutical firms.
abstract: The slow adoption of cytotherapeutics remains a vexing hurdle given clinical progress achieved to date with a variety of stem cell lineages. Big and midsize pharmaceutical companies as an asset class still delay large-scale investments in this arena until technological and market risks will have been further reduced. Nonetheless, a handful of stem cell strategic alliance and licensing transactions have already been implemented, indicating that progress is actively monitored, although most of these involve midsize firms. The greatest difficulty is, perhaps, that the regenerative medicine industry is currently only approaching the point of inflexion of the technology development S-curve, as many more clinical trials read out. A path to accelerating technology adoption is to focus on innovation outliers among healthcare actors. These can be identified by analyzing systemic factors (e.g., national science policies and industry fragmentation) and intrinsic factors (corporate culture, e.g., nimble decision-making structures; corporate finance, e.g., opportunity costs and ownership structure; and operations, e.g., portfolio management strategies, threats on existing businesses and patent expirations). Another path is to accelerate the full clinical translation and commercialization of an allogeneic cytotherapeutic product in any indication to demonstrate the disease-modifying potential of the new products for treatment and prophylaxis, ideally for a large unmet medical need such as dry age-related macular degeneration, or for an orphan disease such as biologics-refractory acute graft-versus-host disease. In times of decreased industry average research productivities, regenerative medicine products provide important prospects for creating new franchises with a market potential that could very well mirror that achieved with the technology of monoclonal antibodies.
authors.affiliation: Sloan Fellowship, London Business School, UK.
authors.forename: Alain A
authors.initials: AA
authors.lastname: Vertès
mesh_terms: D064591:Allografts; D018929:Cell Culture Techniques / Q000191:economics* / Q000379:methods; D064987:Cell- and Tissue-Based Therapy / Q000191:economics*; D004345:Drug Industry / Q000191:economics* / Q000379:methods; D006801:Humans; D033581:Stem Cell Transplantation / Q000191:economics*; D013234:Stem Cells
keywords: big pharma; cytotherapeutics; disruptive innovation; licensing and partnerships; midsize pharmaceutical firms; radical innovation; stem cells; technology adoption; technology deployment